View More View Less
  • 1 Debreceni Egyetem ÁOK, 4032 Debrecen, Nagyerdei krt. 98.
  • | 2 Debreceni Egyetem ÁOK, Debrecen
Open access
  • 1

    Lenartova A, Randen U, Johannesen TB, et al. Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway. Cancer Epidemiol. 2019; 60: 128–133.

  • 2

    Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood 2018; 131: 2761 LP – 2772.

  • 3

    Kanagal-Shamanna R, Jain P, Patel KP, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 2019; 125: 559–574.

  • 4

    Innocenti I, Rossi D, Trap? G, et al. Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematol Oncol. 2018; 36: 600–603.

  • 5

    Guerrero-Hernandez M, Matas-Cespedes A, Serrat N, et al. Idelalisib interferes with the crosstalk of follicular lymphoma and its immune microenvironment and potentiates the activity of ABT-199. Blood. 2017; 130: 2813 LP – 2813.

  • 6

    Pham LV, Huang S, Zhang H, et al. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res. 2018; 24: 3967 LP – 3980.